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A mutation in the POT1 gene is responsible
for cardiac angiosarcoma in TP53-negative
Li–Fraumeni-like families
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Luis Alonso-Pulpon4, Fernando Setien13, Manel Esteller13,14,15, Sandra Rodriguez-Perales16, Gaelle Bougeard17,
Tierry Frebourg17, Miguel Urioste2,12, Maria A. Blasco3,** & Javier Benı´tez1,2,**
Cardiac angiosarcoma (CAS) is a rare malignant tumour whose genetic basis is unknown.
Here we show, by whole-exome sequencing of a TP53-negative Li–Fraumeni-like (LFL) family
including CAS cases, that a missense variant (p.R117C) in POT1 (protection of telomeres 1) gene
is responsible for CAS. The same gene alteration is found in two other LFL families with CAS,
supporting the causal effect of the identified mutation. We extend the analysis to
TP53-negative LFL families with no CAS and find the same mutation in a breast AS family. The
mutation is recently found once in 121,324 studied alleles in ExAC server but it is not
described in any other database or found in 1,520 Spanish controls. In silico structural analysis
suggests how the mutation disrupts POT1 structure. Functional and in vitro studies
demonstrate that carriers of the mutation show reduced telomere-bound POT1 levels,
abnormally long telomeres and increased telomere fragility.
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T
he incidence of primary cardiac tumours is estimated to be
between 0.001 and 0.003% in general population1. Cardiac
angiosarcoma (CAS) is a very rare malignant tumour that
represents o10% of cardiac malignancies Patients are generally
diagnosed at advanced stages with very poor prognosis and short
survivals2. Patients with sporadic AS had a 5-year survival rate of
14% while familial cancer patients had a mean survival time of
4 months. Age of familial CAS onset shows a wide range but most
patients affected are younger than 65 years of age2. Information
about familial CAS is very scarce and as far as we now, only two
families have been reported presenting both an earlier age of
onset than sporadic3,4 No genes responsible for these cases have
been identified so far, thus humpering early diagnosis and
effective treatment, which involves surgical excision combined
with chemotherapy, and heart transplantation only for patients
with no evidence for metastasis.
On the other hand, Li–Fraumeni syndrome (LFS) is
characterized by the presence of different types of tumours
including sarcomas and ASs in multiple locations such as liver,
spleen, breast, head and neck, and rarely heart5. In most cases,
LFS is triggered by the mutations in the TP53 gene (480%),
which is the causal gene that confers susceptibility to the
development of different tumours. In addition, Li–Fraumeni-like
(LFL) families have similar clinical presentation and family
characteristics. However, they are generally diagnosed at a
later age of onset and rarely associated with mutations in TP53
(o20% of cases)6,7.
Here we describe the identification by whole-exome
sequencing of POT1 (protection of telomeres 1) gene as
responsible of TP53-negative LFL families with CAS, as well as
other tumour types.
POT1 is a component of the so-called shelterin complex
(POT1, TRF1, TRF2, TIN2, TPP1 and RAP1) that binds to
telomeres and has fundamental roles in chromosome stability and
regulation of telomerase activity at chromosome ends8,9.
POT1 possesses two N-terminal OB domains, which confer to
this protein high specificity for single-stranded DNA sequence
50-TAGGGTTAG-30, thereby binding to the telomeric G-strand
overhang10–12. In addition, POT1 binds through its C terminus
to TPP1 and anchors POT1 to the shelterin complex at
telomeres13–15. POT1 regulates telomere length (TL) by
preventing telomerase access to telomeres by sequestering the
DNA terminus12,16,17. POT1 loss-of-function mutations have
been related with telomere lengthening and chromosomal
instability18,19. Recently, germline mutations in the POT1 gene
were found in familial melanoma and glioma tumours20–22,
as well as in somatic chronic lymphocytic leukemia (CLL)23.
Here we identify a new missense variant in POT1 (p.R117C) as
responsible of LFL locus specifically associated with CAS and
demonstrate that mutation carriers show reduced telomere-
bound POT1 levels, abnormally long telomeres and increased
telomere fragility, highlighting a new role of POT1 as a high
susceptibility gene in familial cancer and opening therapeutical
opportunities for prognosis and treatment in families with CAS.
Results
Whole-exome sequencing (WES) and candidate variant studies.
A TP53-negative LFL Spanish family with three CAS cases and
eight members with different tumours across generations were
ascertained from the Cancer Genetic Consultancy of CNIO,
(Fig. 1 and Table 1). Two members affected by CAS (II-10 and
III-13) were selected for WES (Fig. 1; Methods for details). About
2(26)1 4(13) 6(13)3 5
2(31)1 3(58) 4
I 
II 
III 2 
2
1 
Family 2
2 
3(59)
2 
3 
1(35)
1
I 
II 
III 
Family 3
7
2
I
II
III
IV
1
1(35)
Family 4
I 
II 
III 
1 
4 4 4 4 2
4(63) 5(63) 6(48) 9(43)7(53) 8 10(45)
1-4
1 2 3
9-125-8 13(24) 14 15(24) 17(23) 1816 19
Family 1
Soft tissue sarcoma 
Malignant schwanoma 
Multiple tumours Mediastinal tumour 
Lung cancer 
Testicular cancer Bladder cancer 
Pancreatic cancer Lymphoma Renal cancer 
Hepatocarcinoma Breast AS  
Liver cancer
Colorectal cancer  Lung adenocarcinoma Non-melanoma skin cancer 
Skeletal-muscle cancer Cardiac AS 
p.R117C mutation carrier 
* Immortalized cell line from lymphocytes **Parafin-embedded tissue Probandus
Melanoma 
7
* *
* *
** **
**
1  
2(39)
Figure 1 | Pedigrees of TP53-negative LFL families. Families 1, 2 and 3 have three, two and one members with cardiac angiosarcomas (CAS),
respectively. CAS and other tumours are shown (colour code below the Fig.). Exomes of blue-squared CAS cases were sequenced. One member of family
4 presented with breast angiosarcoma. Only family members of whom DNA samples were available are numbered (1–19) in bold and italics. Age of
onset (CAS cases) and age of sample (mutation carriers) is shown in brackets. Age of onset of other tumours is shown in the Table 1. ‘*’ indicates
immortalized lymphocyte cell lines from family 1: II-1 and II-4 (64- and 65-years old, respectively) and III-15 and III-16 (34- and 35-years old, respectively).
‘**’ indicates paraffin-embedded tumour tissue available. Black arrows show the probandus for each family.
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85% of target regions were observed with coverage420 . After
filtering according to our homemade pipeline and GATK-based
variant calling (Methods), we only found 394 variants in common
between both samples, which were used for downstream
filtering. Ten variants fulfilled our prioritization criteria, taking
forward annotation and putative damaging effects into account
(Supplementary Table 1). After Sanger validation and segregation
studies in other members of this family, variants annotated
in POT1 (Chr7:124503601G4A), SPEG (chr2:220355477) and
EIF2AK (chr2:37347280) were validated. We decided to further
study POT1, as other germline and somatic mutations of this
gene were recently found in familial melanoma and glioma
tumours20–22, as well as in CLL23, respectively. POT1 variant
found in both CAS members (p.R117C) was highly deleterious
and was neither described in the Exome variant server, Ensembl,
dbSNP, 1000 genomes and COSMIC databases nor present
in melanoma and glioma families with POT1 mutations20–22.
The variant was recently found once (heterozygous) in 121,324
studied alleles (frequency: 8.2 10 6) in ExAC server. p.R117C
mutation was not found in 1,520 Spanish control individuals.
We could study the complete POT1 gene in two additional
Spanish LFL families with CAS (Fig. 1, families 2 and 3) and
strikingly, we found the same variant p.R117C. Then, we
extended the study of the POT1 gene to 19 probands belonging
to TP53-negative LFL families, with no CAS. Nine of them had
developed different AS types and 10 presented with sarcomas
(Table 1). We found one Spanish family with breast AS and other
tumours carrying the same mutation.
We assessed the founder effect of the mutation, by performing
haplotype studies with seven single nucleotide polymorphisms
(SNPs) covering the gene (Methods). Six different haplotypes
were found from the analysis of control Spanish families. Only
families 1 and 2 had enough members for this study and both
presented the most frequent haplotype (42%) (Supplementary
Table 2).
In silico studies. The p.R117 position is highly conserved across
selected representative species that suggest the same residue for
the last common ancestor within the phylogeny (Fig. 2a).
Table 1 | Tumour types of different members of the studied families.
p.R117C Family Tumour type
Sarcoma Breast CNS Melanoma Lung Other Multiple primary
tumours*
Angiosarcoma Soft Bone NS
Present 1 Carriers 3 CAS
(24,45,58)**
1 (69) 1 (93) 1 (48) 2 (47,61) 1
melanomaþCAS
NT 1 (56) 1 (43)
2 Carriers 2 CAS (32,41)
NT 1 liver (54) 1
kidney (50)
3 Carriers 2 CAS (40)
4 Carriers 1 breast (32) 1 PTC (35) 1 BAþ PTC
NT 1 lymphoma
(38)
Not
Present
5 3
(41,45,50)
1 (U) 2
astroc.
(12,24)
1 NHL
neurofibromas
(24)
1 astroc.
þNHLþCM
6 1 (42) 1
astroc.
(12)
1 CRC (40)
7 2 (45,49) 2 stomach
(65,68), 2 CCR
(27,71)
8 1 (2) 1 (44) 1 (63) 1 CRC (58)
9 1 (21) 2 (45, 45)
10 2 (2,15) 1 (45) 1 EC (16) 1 CRC
(26)
1
STSþ ECþCRC
11 2 (13,38) 1 (35) 1 STSþ BC
12 2 (54,68)
13 1 (7) 1 (28) 1
bilateral
(35,39)
1 (54) 1 kidney 1 CM
14 1 (U) 2 (U) 1 GBM
(U)
1 stomach, 1
ovarian 1 NHL
1 BCþ STS
15 1 breast (22) 2 (43,50) 1 head&neck
(45) 1CRC (70)
16 1 chest wall
(56)
1 bilateral
(48,61) 1
(80)
1 peritoneum
(58)
1 CMþAS
17 1 breast (32) 1 ALL (15) 1 ALLþ BA
18 1 breast (57) 2 (49,58) 1 prostate (51) 1 CMþ BA
19 2 bilateral
breast (37,39)
1 (50) 1 (60)
20 1 breast (42) 1 bilateral
(37,45) 1
(64)
1 CMþ BAþ BC
21 1 thigh (17) 1 (U)
22 1 breast (15)
ALL, acute lymphoblastic leukemia; AS, angiosarcoma; astroc., astrocytic tumour; BA, breast angiosarcoma; BC, breast cancer; CAS, cardiac angiosarcoma; CM, cutaneous melanoma; CNS, central
nervous system; CRC, colorectal cancer; EC, endometrial cancer; GBM, glioblastoma multiforme; NHL, non-Hodgkin Lymphoma; NS, not specified; NT, not tested; PTC, papillary thyroid carcinoma;
STS, soft tissue sarcoma; U, unknown.
Tumours of the members of family 1 without DNA sample were NT. Age at diagnosis is shown in brackets.
*Multiple primary tumours refer to tumour types described in one individual.
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p.R117C mutation was located within the OB1/OB2 domains of
the protein, similarly to the germline mutations found in familial
melanoma and glioma20–22 (Table 2). Tolerance to independent
amino acid (aa) substitutions was calculated in a heat map
representation using PredictProtein24 showing a highly
deleterious effect (Fig. 2b).
Position p.117 was found to be part of a short linear peptide
motif of a disordered/unstructured region based on previous
predictions10 (hot loops), which have a critical conformation25
and are related to alterations in predicted accessibility and protein
flexibility. Thus, the PACC (predicted solvent accessibility in
square Angstroem) was calculated for the residues of POT1R117C
protein model that were described to be located within the
OB fold (from p.142 to p.152) and with stacking interaction to
DNA (p.31, p.62, p.89, p.161, p223, p.245, p.266 and p.271) in
POT1 protein according to the study by Lei et al.10 Two residues
(p.152 and p.266) had significantly different PACC scores in
POT1R117C protein model (Supplementary Table 3). p.152 and
p.266 are oriented closed together and located at the border of
domains OB1 and OB2. The consequence of this accessibility
change predicts a disruption of the interaction between OB1 and
OB2 in a putative three-dimensional model of the POT1R117C
protein (Fig. 2c).
To complete the study of these putative conformational
changes observed in POT1R117C, PACC scores for the
same residues were calculated for predicted protein models
encompassing previously described mutations in the OB1 domain
in melanoma and glioma tumours (p.Y89C and p.Q94E20,
p.G95C22, and p.R137H21). Moreover, we also included a
protein model with a deletion from p.1 to p.126 residues
(POT1DOB1) as described by Loayza and De Lange12 and a
second protein model encompassing a deletion of the whole OB1
domain (cd04497: hPOT1_OB1_like (E-value: 3.43e-45); interval
from p.10 to p.141). Both p.152 and p.266 PACC score changes
observed in POT1R117C were not found in the rest of the studied
protein models (Supplementary Table 3).
Finally, we searched for the putative protein–protein-binding
regions of wild-type (wt) POT1 protein and 14 positions
were found to be significantly relevant (threshold420)
(Supplementary Table 4). The same positions were studied in
all mutated protein models. A putative protein-binding region
annotated in position p.499 was significantly lost in the
POT1R117C protein model (Supplementary Table 4). p.499 is a
well-conserved position with high deleterious tolerance to aa
change (86,4) at the conserved POT1 C terminus within the
TPP1-binding domain (Fig. 2b)13. Interestingly, this protein-
binding region was lost in the protein model with the deletion of
the whole OB1 domain (from p.10 to p.141) but was unaffected in
the other mutant models and POT1DOB1 (with a deletion in OB1
domain from p.1 to p.126) (ref. 12).
Expression and protein studies. To study whether the missense
variant (p.R117C) affects POT1 transcriptional and protein levels,
we performed quantitative PCR (qPCR) from complementary
DNA (cDNA) and western blot (WB) analyses from primary
lymphocytes (PL) from carriers and in non-carriers. We found no
significant differences in POT1 mRNA levels in PL from carriers
compared with non-carriers (Supplementary Fig. 1). Similarly,
we did not find significant differences in POT1 protein levels
(two-tailed student’s t-test, P¼ 0.1) as determined by WB
(Supplementary Fig. 1). Next, we set to determine POT1 levels
localized at telomeres by double immunofluorescence with POT1
and TRF1 antibodies (another telomere-binding protein from the
shelterin complex used here to localize telomeres)26. To this end,
we used immortalized lymphoblastoid cell lines (LCLs) derived
from members II-1, II-4, III-15 and III-16 (Fig. 1, family 1).
Immunofluorescence levels with anti-TRF1 antibody were similar
for all family members independently of the carrier status
(Fig. 3a,b). In contrast, the intensity of POT1 telomeric foci was
significantly lower in p.R117C carriers (two-tailed student’s t-test,
Po0.0001) than controls and there was also a decrease in the
number of co-localizations (Fig. 3a,b).
To address the effect of this mutation on the binding of POT1
to telomeric chromatin in vivo, we performed chromatin
immunoprecipitation (ChiP) with the four LCLs using antibodies
against POT1, TRF1 and TRF2 (Methods). The hybridization
signal of telomeric DNA immunoprecipitated with anti-TRF1 and
anti-TRF2 (positive telomeric controls) was not significantly
different in mutation carriers compared with non-carriers
(Fig. 3c). However, a significant reduction of hybridization
signal was observed in mutation carriers when telomeric DNA
was immunoprecipitated with anti-POT1 antibodies (two-tailed
student’s t-test, P¼ 0.004).
POT1 is recruited to telomere through interaction with TPP1
(ref. 13). The reduced levels of telomere-bound POT1 observed in
mutation carriers (Fig. 3a–c), as well as the in silico analysis
(Supplementary Table 4) suggest that POT1R117C might be
defective in TPP1 binding. To test this, we performed co-
immunoprecipitation assays with in vitro-translated MYC-tagged
POT1R117C and FLAG-tagged TPP1. As controls, we used
MYC-tagged wt POT1 and a mutant MYC-POT1DOB1 that has
been shown to be defective in single strand DNA binding but
functional in its interaction with TPP1 (ref. 12). In addition, we
also used a FLAG-tagged mutant TPP1OBD that lacks both the
POT1 and TIN2 interaction domain27. Equal amounts of the
different MYC-POT1 and FLAG-TPP1 variants were mixed as
indicated and TPP1-POT1 complexes immunoprecipitated
with anti-MYC antibody (Fig. 3d; Supplementary Fig. 2). As
expected, FLAG-TPP1 was pulled down with MYC-POT1 and
MYC-POT1DOB1 while FLAG-TPP1OBD was not detected with
any of the POT1 variants used in the assay. However, immuno-
precipitation of MYC-POT1R117C recovered FLAG-TPP1 to a
much lesser extent than wt MYC-POT1. Indeed, FLAG-TPP1 was
only faintly detected when the immunoblots were developed
under long exposure time (Fig. 3d). These results confirmed that
mutant POT1R117C is affected in its ability to bind TPP1.
We next sought to determine whether the p.R117C substitution
affected the ability of POT1 to bind to the 30 end of the G-rich
telomeric overhang, as suggested by the in silico analysis. In vitro-
translated MYC-POT1, MYC-POT1DOB1 and MYC-POT1R117C
were incubated with radio-labelled telomeric single-stranded
DNA (ssDNA) and with c-MYC (9E10) antibody. Visualization
of the protein-DNA complexes by electrophoretic mobility
shift assay confirmed that wt POT1 efficiently bound telomeric
ssDNA, whereas POT1R117C bound telomeric ssDNA less
efficiently (Fig. 3e; Supplementary Fig. 2). As expected,
POT1DOB1 was unable to bind to the telomeric sequence.
Studies in telomeres. In line with dysfunctional POT1 that is
usually associated with increased DNA damage at telomeres
(the so-called telomere-induced foci (TIF)) and occurrence of
telomere fragility, we observed significantly increased multi-
telomeric signal events (MTS) in mutation carriers compared
with non-carriers (two-tailed student’s t-test, Po0.0001) (Fig. 3f)
and an increase of positive cells for gH2AX (two-tailed student’s
t-test, P¼ 0.05) a DNA damage marker (Fig. 3g). Double
immunofluorescence staining with gH2AX and TRF1 antibodies
was performed to determine TIFs. The results showed a sig-
nificant increase in the percentage of cells with more than five
TIFs in carriers as compared with non-carriers (two-tailed
student’s t-test, P¼ 0.003) (Fig. 3g). Of note, we did not observe
end-to end fusions in mutation carriers.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9383
4 NATURE COMMUNICATIONS | 6:8383 | DOI: 10.1038/ncomms9383 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
We evaluated the effect of the p.R117C mutation in TL.
We measured it by qPCR in peripheral blood lymphocytes
from members of family 1. TL values were adjusted for age.
We consistently found longer telomeres in mutation carriers
compared with non-carriers (two-tailed student’s t-test, P¼ 0.02)
(Fig. 4a). TL was also calculated with fluorescence in situ
hybridization quantitative detection (quantitative fluorescence
in situ hybridization (qFISH))28 and we validated that TL was
significantly longer in mutation carriers compared with controls
(two-tailed student’s t-test, Po0.0001) (Fig. 4b). In addition, a
higher percentage of short telomeres o3 kb was found in non-
carriers compared with p.R117C mutant carriers comparing older
members (II-1 and II-4, 64.5 old in average) (Fig. 4c). Otherwise,
no significant differences among members of family 1 were found
regarding in vitro telomeric repeat amplification (TRAP)
telomerase activity (Fig. 4d).
Abnormal telomeres elongation could be the consequence of
increased telomere recombination, to the so-called alternative
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Table 2 | Deleterious germinal mutations described in the POT1 gene.
Position Allele Exon Amino acid change Domain Source
g.124503601 G4A 4 p.Arg117Cys OB1 *
g.124503684 T4C 4 p.Tyr89Cys OB1 Robles-Espinoza et al.20
g.124503670 G4C 4 p.Gln94Glu OB1
g.124493077 C4A 6 p.Arg273Leu OB2
g.124465412 C4T 14 Splice site Telomere/TPP1 binding
g.124503540 C4T 4 p.Arg137His OB1 Shi et al.21w
g.124499043 C4T 5 p.Asp224Asn OB2
g.124493086 C4T 6 p.Ser270Asn OB2
g.124469308 C4G 13 p.Ala532Pro Telomere/TPP1 binding
g.124464052 C4G 15 p.Gln623His Telomere/TPP1 binding
g.124503667 C4A 4 p.Gly95Cys OB1
g.124481048 C4A 10 p.Glu450z Telomere/TPP1 binding Bainbridge et al.22
g.124464068 TTA4T 15 p.Asp617Glu (fs) Telomere/TPP1 binding
fs, frame shift; POT1, protection of telomeres 1.
*Mutation described in the present study.
wFounder mutation.
zStop codon.
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were performed. a.u.f., arbitrary units of fluorescence. (b) Representative images of TRF1 (red) and POT1 (green) double immunofluorescence in wild-type
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decreased POT1 binding capacity to TPP1. Co-immunoprecipitation assays of the in vitro-translated proteins. FLAG-TPP1 was pulled down with MYC
antibody and revealed by FLAG antibody. FLAG-TPP1 lacking the TIN2 and POT1 binding domain, FLAG-TPP1OBD, and a POT1 mutant lacking its OB1
domain were used as controls. Two exposures are showed. (e) p.R117C substitution decreased POT1 binding capacity to telomeric ssDNA. Electrophoretic
mobility shift assay of [32P]-labelled oligonucleotide (50-TTAGGG-30)7 in the presence of the indicated in vitro-translated POT1 proteins. Data from two
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triplicate). Lower panel: representative images of gH2AX and TRF1 immunofluorescence. White arrows show examples of TIFs (yellow spots) with
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lengthening of telomeres (ALT). We evaluated this possibility by
quantification of recombination events specifically at telomeric
repeats, the so-called telomere sister chromatid exchanges
(T-SCEs). We observed a similar frequency of T-SCE in
mutations carriers (0.43±0.14) compared with wt controls
(0.29±0.19) (Fig. 4e) ruling out a possible ALT mechanism of
telomere elongation in lymphocytes.
Finally, paraffin-embedded tissues were also studied. Loss of
heterozygosity of POT1 locus was evaluated in four CAS tumours
from families 1 and 2. Loss of heterozygosity was observed in only
one of the studied cases while the other three cases presented a
heterozygosis profile. The three CAS tumours from families 2 and
3 (one also with normal cardiac tissue) were also studied for
ultra-bright spots (ubs) in telomeres. FISH for ubs in telomeres
showed an increased number of ubs-positive signals (5.56 positive
signals 100/total signals on average) compared with normal
tissue (0.68 positive signals 100/total signals; Fig. 4f). This
alteration correlated with the TL of tumours, which was highly
increased compared with wt samples (P¼ 0.0001) and mutation
carriers (P¼ 0.0075) adjusted for age (two-tailed student’s t-test)
(Fig. 4g).
In vitro experiments. As the identified mutation is present in
heterozygosis in all the analysed carriers, we hypothesize that
POT1R117C protein functions in a dominant-negative manner.
To further validate this possibility, we create heterologous Hela
cell lines using retroviral vectors to express wt MYC-POT1,
MYC-POT1R117C and MYC-POT DOB1 alleles26 in the presence of
endogenous POT1. Double immunofluorescence microscopy
analysis with MYC and TRF1 antibodies of Hela cells showed
that wt and mutant Myc-POT1DOB1 proteins but no cells
expressing the MYC epitope alone (empty vector) show
colocalization of both telomeric proteins MYC-POT1 and
TRF1. Hela cells expressing MYC-POT1R117C showed a similar
pattern than those expressing the vector alone and only few cells
presented few MYC foci that colocalized with TRF1 (Fig. 5a,b).
Quantification of TRF1 nuclear intensity revealed no significant
differences among Hela cells expressing either the empty vector
or the wt and mutant POT1 alleles (Fig. 5a,b). Decreased amount
of telomere bound of MYC-POT1R117C protein in Hela cells is in
agreement with the decreased amount of protein observed in
lymphocytes by immunofluorescence and ChIP analysis using
POT1 antibodies (Fig. 3a–c).
To address, whether heterologously MYC-POT1R117C over-
expression recapitulates the observed effects in lymphocytes
we analysed the functional effects of POT1R117C expression
in Hela cells. TL in Hela cells infected with retroviral empty
vector, MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1 was
measured by quantitative telomere FISH on metaphase spreads.
Increased TL was observed in both Hela cells expressing
MYC-POT1DOB1 and MYC-POT1R117C compared with both cells
infected with empty vector and MYC-POT1 after 30 population
doublings (Fig. 5c,f).
Finally, analysis of chromosome aberrations in metaphase
spreads of the different transduced Hela cells, revealed a moderate
but significant increase in MTS events in those expressing
MYC-POT1R117C and MYC-POT1DOB1 as compared with those
expressing either the empty vector or wt MYC-POT1 (Fig. 5d,f).
In addition, an increase in gH2AX-positive cells was detected
in Hela cells infected with MYC-POT1R117C as compared with
those harbouring either the empty vector, MYC-POT1 wt or
MYC-POT1DOB1 (Fig. 5e).
Discusion
We have found a novel damaging missense variant (p.R117C) in
the POT1 gene in TP53-negative LFL families with CAS and other
tumours. Mutations in POT1 were recently associated with
familial melanoma20,21 and glioma22 and as a driver for CLL23,
uncovering a new role of this gene not only as telomere protector,
but also as one of the main responsible genes for development of
different familial cancer types. The mutation was the same in the
four studied families. Haplotype studies suggested a possible
founder effect within the Spanish population although larger
studies are necessary to confirm this issue.
There are several consequences of this mutation that we have
demonstrated by in silico, in vivo and in vitro studies. Thus,
in silico studies showed that the p.R117C substitution putatively
disrupted the interaction between OB1 and OB2 (Fig. 2d) and
affect the protein-binding site to TPP1 (Supplementary Table 4),
which might result in the loss of capability of the POT1R117C
protein to interact with ssDNA and to be recruited to telomeres.
The predicted conformation change might be explained as a
consequence of the substitution of a polar basic aa (Arginine)
with a non-polar thiol aa (Cysteine) at position p.117 with the
capability to generate disulfide bonds.
In silico analyses were confirmed by in vivo assays analysing
the binding of mutated POT1 protein to telomeres. Double
immunofluorescence with POT1 and TRF1 in immortalized LCLs
suggests that the variant has an important effect on the levels of
POT1 at telomeres by showing significant decreased levels in
mutation carriers. In vitro assays demonstrated that POT1R117C is
deficient at both, in TPP1 interaction and in telomeric ssDNA
binding, affecting POT1 function.
Although the mutation was located within the OB1/OB2
domains of the protein, similarly to the germline mutations found
in familial melanoma and glioma20–22 (Table 2), it was specific of
CAS. In fact, only a member from family 1 carrying the mutation
(II-6) developed melanoma, and no members from reported
families with melanoma or gliomas carrying POT1 mutations
presented CAS20–22. The fourth family (Fig. 1, family 4) did not
have any member with CAS but the family structure was small
and we cannot rule out the possibility that asymptomatic carriers
of the mutation will develop a CAS in the future.
These findings stress the importance of POT1 domains in
cancer development and raise the intriguing open question about
the correlation between the genotype and the phenotype. Our
in silico studies suggest that the putative conformational changes
in POT1 proteins due to the mutations described in melanoma
and glioma tumours are different from those observed for
POT1R117C (Supplementary Tables 3 and 4). Because POT1 is
described in tight coordination with the rest of shelterin complex
proteins, we cannot rule out that different conformational changes
might have different effects on the shelterin complex function.
Similarly to other members of the shelterin complex, disrup-
tion of POT1 function was associated to increased DNA damage
at telomeres and occurrence of telomere fragility23. In our case,
defective POT1R117C function has shown to lead to a moderate
increase in MTS, and in telomere DNA damage, that could
account for the genomic instability that these cases present.
Moreover, increased TL was confirmed in mutation carriers. This
is in agreement with previously described POT1 mutations in
CLL and familial melanoma and glioma patients that showed
abnormally elongated telomeres20–23. In our cases, TL was
markedly different between mutation carriers and non-carriers
within older members, suggesting that there was a cumulative
effect in telomere elongation with age (Fig. 4b,c). Differences
observed in the amount of telomeres shorter than 3Kb in older
members suggest a downfall in the telomere shortening through
aging, indicating abnormal telomere biology in mutation carriers.
We showed similar in vitro TRAP telomerase activity levels in
both carriers and non-carriers, indicating no defects in telomerase
assembly or function (Fig. 4d). Thus, the longer telomeres
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observed in mutation carriers are rather due to alterations in
in vivo telomerase recruitment and function on telomeres. In fact,
POT1 has been shown to be important to prevent telomerase
access to telomeres by sequestering the DNA terminus12,16,17. We
show that POT1R117C is defective in both binding to TPP1 and
binding to ssDNA telomeric DNA. It is therefore tempting to
speculate that POT1R117C fails to inhibit telomerase due to the
reduced telomere-bound POT1R117C, as well as to defective
binding to telomeric G-strand overhang. In addition, given the
defective binding of POT1R117C to single G-strand overhang
(Fig. 3d,e), telomeric damage could also stem from defective
maintenance of the 30 G-strand overhang needed for proper
T-loop formation. Indeed, abnormal telomere elongation due to
the consequence of increased telomere recombination (ALT) was
ruled out as no differences in T-SCE were found in lymphocytes
between carriers and non-carriers. Thus, lack of functional POT1
seems to affect telomere structure and expose them to abnormal
elongation by a normal telomerase activity.
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Figure 4 | POT1R117C carriers present longer telomeres. (a) Telomere length (TL) analysis by qPCR (t/s ratio) for family 1 members (n¼ 29).
(b) TL analysis by qFISH of primary immortalized LCLs corresponding to non-carriers (II-1 and III-16) and p.R117C carriers (II-4 and III-15). (c) Percentage
of telomeres shorter than 3 kb of primary immortalized LCLs corresponding to non-carriers (II-1 and III-16) and p.R117C carriers (II-4 and III-15). (d) TRAP
Tel/IC ratio values for telomerase activity calculated from primary lymphocytes of different members of family 1 (n¼ 7). In b–d two independent
experiments with samples in triplicate were performed. (e) Left panel: number of telomere sister chromatid exchange (T-SCE) events/metaphase in
primary lymphocytes by CO-FISH (n¼ 2 individuals per genotype in triplicate). Right panels: representative CO-FISH images showing the leading (green)
and lagging (red) telomere strands. T-SCEs are indicated with arrows. DAPI (blue) was used for DNA labelling. Below a magnified merge image is shown.
Scale bar, 1mm. (f) Upper panel: per cent of cells positive for ultra-bright spots (ubs) at telomeres by FISH in three different paraffin-embedded cardiac
tumour (T) and normal (N) tissue samples carrying the mutation from members of family 2 (F2) and 3 (F3). Lower panel: examples of large red spots
corresponding to positive signals (white arrows). DAPI (blue) was used for DNA labelling. Scale bar, 10mm. (g) TL adjusted for age of wt and p.R117C
carriers of all members of families 1, 2 and 3 and the 3 CAS tumours. DNA from CAS samples was extracted from paraffin-embedded tissues. Values are
expressed as meanþ s.e. and the two-tailed student’s unpaired t-test was used for the statistical analysis, NS, not significant.
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Figure 5 | Heterologous POT1R117C expression induces telomere lengthening. (a) Representative images of MYC (green) and TRF1 (red) double
immunofluorescence in Hela cells with endogenous expression of POT1 protein infected with retroviral empty vector, MYC-POT1, MYC-POT1R117C and
MYC-POT1DOB1. DAPI (blue) was used to DNA labelling. Scale bar, 5 mm. (b) Quantification of MYC-POT1 and TRF1 colocalization foci (left panel) and of
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(d) in Hela cells infected with retroviral empty vector, MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1. (e) Per cent of gH2AX-positive cells in Hela cells
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Two independent infections were performed. Values are expressed as meanþ s.e. The two-tailed student’s unpaired t-test was used for the statistical
analysis, NS, not significant.
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The telomeric phenotypes observed in lymphocytes from
p.R117C variant carriers were validated by in vitro studies in
Hela cell lines created using retroviral vectors expressing wt
MYC-POT1, MYC-POT1R117C and MYC-POT1DOB1 (ref. 26)
in the presence of endogenous POT1. We confirmed that
the POT1R117C protein acts in a dominant-negative manner,
analogous to that previously reported for the POT1DOB1
mutant26, as well as for others POT1 variants found in CLL23.
In this system, we also detected decreased POT1R117C protein
levels at telomeres, moderate increase in MTS incidence, higher
telomeric DNA damage and a telomere lengthening effect. So, it is
tempting to speculate that telomere elongation induced by this
mutation in POT1 may constitute the underlying molecular
mechanism favouring tumour incidence.
The identification of POT1 mutation in CAS is important,
since it provides the possibility for earlier diagnosis of people at
risk. Currently this tumour is diagnosed in advanced stages when
distant metastases are present and the survival is very poor, as
surgical resection is not effective. Larger studies are necessary to
fully assess the clinical spectrum associated with this mutation
and other mutations along the whole POT1 gene. Future work is
needed to address POT1R117C relation not only with familial but
also with sporadic CAS and its role in LFL cases including ASs
other than cardiac.
Methods
Patients. Index cases from LFL families negative for mutations and large deletions
of the TP53 gene were selected for this study. Three of our families had members
affected with CAS plus other tumours (Fig. 1). The rest of the families fulfilled the
LFL criteria but they did not have any member with a CAS tumour (Table 1).
Families were selected from the Spanish National Cancer Research Center (CNIO),
Hospital Puerta de Hierro and Clara Campal Center (Spain), and Rouen University
Hospital (France). DNA from most of the family members and whenever possible
total mRNA and protein were collected from lymphocytes.
A group of 1,520 samples from a Spanish control population was used
for genotyping the POT1 variant by denaturing high performance liquid
chromatography29. Heteroduplex was amplified with primers of the exon 4, which
encompassed the candidate variant (Supplementary Table 5). Genotyping was
performed with WAVE Nucleic Acid Fragment System from Transgeomics and
Navigator Software. Amplification was performed with standard conditions
((95 C, 5min; (44 C, 30 seg.; 64 C, 30 seg.; 72 C, 45 seg.) 30 cycle; 72 C,
10min.).
The study was approved by the ethics committee of the different centres and
informed consent was obtained from all participants.
Establishment of B LCLs. Lymphoblasts from different members of family 1 were
immortalized: II-1 (aged 64), II-4 (aged 65), III-15 (aged 35) and III-16 (aged 34).
LCLs were established by Epstein–Barr virus (EBV) transformation/infection
of peripheral blood mononuclear cells (PBMC)30. PBMCs were incubated with
B95-8 cell supernatant (containing EBV in the presence of 10 mgml 1 of
phytohemagglutinin in R.P.M.I1640 supplemented with 20% (v/v) heat-inactivated,
foetal calf serum, 2mM of L-Glutamine, 100Uml 1 of penicillin, 100mgml 1 of
streptomycin and 0.5 mgml 1 of Amphotericin B (Gibco, Invitrogen)). Cells were
plated and incubated at 37 C, 5% CO2 and routinely grown in R.P.M.I1640 culture
medium supplemented with 10% heat-inactivated foetal calf serum, 2mM of
L-Glutamine, 100Uml 1 of penicillin and 100 mgml 1 of streptomycin.
Paraffin-embedded tissue samples. Paraffin-embedded tissue samples of CAS
members from families 2 and 3 were collected (Fig. 1). DNA was extracted using
the DNeasy Blood & Tissue Kit (Cat. No. 69504, Qiagen) following the manu-
facturer’s instructions. Selected tumour tissue was evaluated a pathologist (C.S.).
Whole-exome sequencing. Exomes from two members of family 1 with CAS
(II-10 and III-13) were captured and enriched using the SureSelect Human All
Exon Kit (78Mb) (Agilent Technologies). Enriched samples were paired-end
sequenced on an Illumina Genome Analyzer II sequencing platform, using two
lanes per sample and generating 78-bp-long reads. Filtering of reads and variant
calling were done with the Rubioseq software suite of parallelized pipelines31. PCR
duplicates, overrepresented sequences and low quality reads were filtered with a
modular set of analyses considering per base and per sequence quality scores
(Fastqc 430) and N content.
BWA files of short reads were aligned with the genome of reference
(GRCh37/hg19). GATK-based variant calling was performed for aligned reads
considering DP (read depth) values of430 and QD (quality by depth) scores for a
variant confidence of 41.00. A MAF o3% of was considered. Variants were also
filtered by position (non-synonymous, essential splice site, frame shift or gain/loss
of stops). Their potential damaging effect was assessed using the VEP32 script
software package (including Sift, Polyphen and Condel damage predictors) from
Ensembl.
Filtered variants were prioritized for segregation studies when they were
(i) previously described in other pathogenic processes (COSMIC database),
(ii) annotated in genes with related functions or involved in tumourogenetic
processes, and (iii) annotated in genes suggested to be related to cardiac function.
Prioritized variants from 10 candidate genes were validated by Sanger
sequencing and segregation studies were performed among the different members
of family 1. Candidate variants that were found in the three CAS cases and
mediastinal tumour patients were selected. PCR was performed using standard
conditions (95 C, 5min; (44 C, 30 s.; * C, 30 s.; 72 C, 45 s) 30 cycle; 72 C,
10min). *: C annealing of the corresponding primer. Sequences of the primers are
listed in Supplementary Table 5.
POT1 gene study. Sanger sequencing of the candidate POT1 variant was
performed in 19 probands from LFL families negative for TP53 mutations. The
entire POT1 gene was sequenced for cases negative for the candidate mutation. The
primers used for Sanger sequencing of the 15 exons are listed in Supplementary
Table 5. PCR was performed using standard conditions ((95T C, 5min; (44T C,
30 s; *T C, 30 s; 72 C, 45 s) 30 cycle; 72T C, 10min). *: T C annealing of the
corresponding primer.
Haplotype study. A haplotype study was performed to confirm the possible
founder effect of our variant. Seven SNPs covering the gene were used
(Supplementary Table 2). Selected trios (parent and two offspring) from families
1 and 2 were studied to establish the haplotype carrying the mutation. Trios from
15 healthy Spanish families were used to determine the different haplotypes in the
Spanish population and their frequencies. The primers used for Sanger sequencing
of the seven SNPs are listed in Supplementary Table 5.
Real-time qPCR. Expression studies for POT1 gene genes was performed with
Real-Time qPCR with cDNA obtained from reverse transcription of 1,200 ng of
total RNA from PBMCs using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems #4368814). PCR was carried out with B25 ng ml 1 of cDNA
and the POWER SYBR green PCR Master Mix (Applied Biosystems #4367659).
Quantification was performed using Sequence Detection System 7900HT (Applied
Biosystems). Expression levels were evaluated with the DDCt method33 in triplicate
and normalized to the expression levels of GAPDH, which was used as a standard.
PCR was run with exon 10 forward primer and exon 11 reverse primer to avoid
amplification of genomic DNA (Supplementary Table 5). PCR was performed
using standard conditions (95T C, 5min; (44T C, 30 seg.; 58T C, 30 seg.; 72 C,
45 seg.) 30 cycle; 72T C, 10min).
Western blotting. WB was performed with 50 mg of total protein isolated
from lysed PBMCs. Protein expression levels of POT1 were determined using
rabbit polyclonal anti-POT1 antibody and normalized to GAPDH levels using
anti-GAPDH antibody (Supplementary Table 6). The hybridization signal was
quantified using ImageJ 1.43 u software (W. Rasband, the National Institutes of
Health). Protein expression was evaluated with the DDCt method33.
ChIP assay. ChIP assays were performed with LCLs from family 1. Cells in culture
were cross-linked with formaldehyde (1%) during 15min at room temperature.
The cross linking reaction was stopped by addition of glycine (0.125M) during
5min. Cells were washed twice with cold PBS, collected by centrifugation and lysed
in lysis buffer (1%SDS, 10mM EDTA, 50mM Tris-HCl pH 8.0, protease inhibitors
(P8340, Sigma)). Protein/DNA extracts were sonicated and centrifuged at
14,000 r.p.m. for 15min. Protein concentration was determined (DC protein
assay, Bio-Rad), and chromatin from 200 mg total protein extract was used per
immunoprecipitation with 4 ml of either anti-POT1, anti-TRF2 or anti-TRF1
antibody (Supplementary Table 6) and protein A/G PLUS-agarose beads (Santa
Cruz Biotechnology, sc-2003)34. The immunoprecipitated DNA was transferred to
a Hybond Nþ membrane using a dot-blot apparatus. The membrane was then
hybridized with a telomeric probe containing 1.6 kb of 50-TTAGGG-30 repeats.
Quantification of the signal was performed with ImageQuant software (Molecular
Dynamics). The amount of telomeric DNA after ChIP was normalized to the total
input telomeric DNA.
Bioinformatics tools to assess the in silico studies. Heat map representation of
independent substitutions for each position of the protein and aa tolerance test was
performed with PredictProtein24. Secondary structures (b-strands, a-helix and
loops) of the putative POT1 model were based on REPROFSec prediction. The
predictions of the annotation (minimum REPROFSEc score of 5) of conserved
secondary structures and evolutionary profiles for POT1 carrying the p.R117C
mutation were based on several original prediction methods (NORSnet,
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DISOPRED2, PROFbval and Ucon) implemented in PredictProtein24. Solvent
accessibility notation (PACC) was annotated using the PROFAcc prediction
algorithm35 also implemented in ProteinPredict24. Protein binding regions were
found using the ISIS algorithm36 and SomeNA predictor method (also
implemented in ProteinPredict24). Annotation of residues was based on
crystallography studies of POT1 (ref. 10). A homology-based three-dimensional
model of human POT1 was taken from Uniprot (Q9NUX5). Protein modelling for
POT1 carrying the p.R117C mutation (PSI_SBKB) was performed using the
Protein model portal (available at http://www.proteinmodelportal.org/).
Real-time qPCR of TL. TL was measured by qPCR using DNA from blood
samples. Quantification of TL (t/s ratio) was done through quantification of
telomere repeat copy number (t) and the 36B4 reference gene (s)37. Telomere
repeats were amplified with TEL primers (tel 1, 50-GGTTTTTGAGGGTGAGG
GTGAGGGTGAGGGTGAGGGT-30 ; tel 2, 50-TCCCGACTATCCCTATCCCTA
TCCCTATCCCTATCC-CTA-30), and 36B4 gene was amplified with 36B4u
(50-CAGCAAGTGGGAAGGTGTAATCC-30) and 36B4d (50-CCCATTCTATCA
TCAACGGGTACAA-30) primers37. The final TL value for each sample was
determined under standard conditions in three independent measurements.
Independent measurements had a correlation of r 0.80. The coefficient of variation
was obtained for telomere (average 5%, range 1–50%) and 36B4 (average 1.7%,
range 0.02–16%). TL values were adjusted for age by calculating a regression line
with 330 DNA controls38. Each sample was adjusted for the difference between the
observed TL and the predicted value using the regression line. Following this
method we adjusted t/s values obtained by qPCR (y¼  0.0174xþ 1.96). PCR was
performed using standard conditions (see real-time qPCR section).
High-throughput qFISH. Mononuclear cells (150,000) from PBMCs were plated
in triplicate onto Poly-L-Lysine pre-coated Greiner 96-well plates for 4 h at 37 C.
Poly-L-Lysine was removed before cell addition (100,000 lymphocytes per well).
When lymphocytes attached to the wells, cells were washed three times with
PBS and then fixed during 1 h at room temperature with methanol/acetic acid
(3:1 vol/vol). The plates were overnight dried at 37 C. The cells were rehydrated in
PBS during 15min, fixed for 1min in 4% formaldehyde, treated with pepsin
(1mgml 1, pH 2.0) at 37 C for 10min, washed with PBS, fixed for 1min in 4%
formaldehyde, washed with PBS and dehydrated in a ethanol series (70, 90, 100%).
The Cy-3-labelled (C3TA2)3 PNA probe (Perseptive Biosystems, Bedford, MA) was
dissolved in a hybridization buffer containing 70% formamide/10mM Tris pH
7.0/0.25% (w/v) blocking reagent (0.5 mgml 1) (Dupont, Boston, MA). The
hybridization mixture was placed onto the wells, followed by DNA denaturation
(5min, 85 C). After hybridization (2 h, room temperature), slides were
washed twice with 70% formamide/0.1% BSA/10mM Tris pH 7.2 for 15min,
followed by three washes of 5min in TBS-Tween 0.08% containing DAPI
(40 ,6-diamidino-2-phenylindole). The cells were dehydrated in a ethanol series
(70, 90, 100%) and air dried. Finally, Moviol mounting medium was added to
the wells28. Wells were sealed (Alumaseal; Sigma-Aldrich) and stored at 4 C in
the dark. Samples were processed by High-throughput microscopy within 48 h
after sample preparation by using the Opera-Acapella system (Perkin Elmer) for
image acquisition and analysis28. TL values were calculated using individual
telomere spots.
Telomeric FISH on metaphase spreads. Primary mononuclear cells from
peripheral blood (PBMCs) were stimulated with 7.5 ngml 1 12-O-
tetradecanoylphorbol-13-acetate in R.P.M.I medium supplemented with FBS,
penicillin-streptomycin, b-mercaptoethanol, sodium pyruvate, nonessential aa and
L-glutamine. Colcemid was added at a concentration of 0.1 mgml 1 during 12 h.
Cells were then recovered, subjected to hypotonic shock and fixed in methanol/
acetic acid (3:1). QFISH hybridization on metaphase spreads was performed as
described above for HT-QFISH39. Metaphase spreads were captured on a Leitz
Leica DMRB fluorescence microscope. At least 10 metaphase spreads per subject
were analysed, and chromosomal aberrations were quantified and represented as
frequency per metaphase.
Measurement of T-SCE events by chromosome orientation FISH. Measurement
of sister telomere recombination events (T-SCE) was performed using chromo-
some orientation FISH (CO-FISH). Mononuclear cells from peripheral blood
(PBMCs) were stimulated as above and sub-cultured in the presence of BrdU
(50-bromo-20-deoxyuridine; Sigma) at a final concentration of 1 10 5M, and
then allowed to replicate their DNA once at 37 C for 24 h. Colcemid was added at
a concentration of 0.1 mgml 1 during the last 6 h. Cells were then recovered,
subjected to hypotonic shock and fixed in methanol/acetic acid (3:1). CO-FISH was
performed using first a telomeric (50-CCCTAA-30)7 PNA probe labelled with Cy3
and then a second telomeric (50-TTAGGG-30)7 PNA probe labelled with Alexa-488
(Supplementary Table 6)40. Metaphase spreads were captured on a fluorescence
microscope (DMRB).
Retroviral expression. The pLPC-human MYC-POT1 and pLPC-human MYC-
POT1DOB1 (deleted OB1 domain) plasmids were a gift of de Lange (Addgene
plasmid 12387 and 13241)12. The POT1 variant encoding p.R117C change,
MYC-POT1R117C, was generated by site-directed mutagenesis of the pLPC-human
MYC-POT1 using the QuickChange XL site-directed mutagenesis kit (Agilent
Technologies) using oligonucleotides hPOT1-R117C-F (50-gggagcccctatcatacctTgc
acttcaagcaagtat-30) and hPOT1-R117C-R (50-atacttgcttgaagtgcAaggtatgataggggct
ccc-30). Retroviruses were packaged in 293T cells (ATCC-CRL-3216) using
pCL-Ampho packaging vector. Hela cells (ATCC-CCL-2) were seeded onto p-10
plates to 30% of confluency 24 h before infection. Three consecutive infections
every 12 h were performed by adding 5ml of viral supernatant. Cells were allowed
to recover for 24 h in growth medium before undergoing selection with puromycin
for 3 days. Cells then underwent serial passaging and collected at the indicated
population doubling points.
Inmunofluorescence staining techniques. Lymphoblastoid (this work) and Hela
(ATCC-CCL-2) cells were plated onto Poly-L-Lysine pre-coated coverslips, treated
for 5min with Triton X-100 buffer41 for nuclear extraction, fixed for 10min in 4%
buffered formaldehyde, permeabilized with 0.2% PBS-Triton for 5min and blocked
with foetal bovine serum in PBS for 1 h. Samples were incubated o/n at 4 C with
the primary antibody at 1:250 dilution. TIFs were detected using rabbit polyclonal
anti-TRF1 and a mouse monoclonal antibody raised against phospho-histone2
H2AX-Ser139 (gH2AX) (Supplementary Table 6). Telomeric POT1 and TRF1 foci
were detected using a rabbit polyclonal anti-POT1 and a mouse monoclonal
antibody anti-TRF1 (Supplementary Table 6). MYC-POT1 was detected using a
mouse monoclonal c-MYC antibody. Slides were further incubated with 488-Alexa
or 555-Alexa-labelled secondary antibodies (Supplementary Table 6). Slides were
mounted in Vectashield with DAPI. Confocal microscopy was performed at room
temperature with a laser-scanning microscope (TCS SP5; Leica) using a Plan Apo
63Å-1.40 numerical aperture oil immersion objective (HCX; Leica). Maximal
projection of Z-stack images generated using advanced fluorescence software (LAS)
was analysed with the Definiens XD software package. The DAPI images were used
to detect signals inside the nuclei.
TRAP analysis. Telomerase activity was measured using protein extract from
PBMCs cultured in RPMI supplemented with 20% FBS and phytohemagglutinin
during 4–5 days. Telomerase activity was determined under recommended
standard conditions of the TRAPEZE Telomerase Detection S7700 Kit (Millipore)
for TRAP using radioisotopic detection. Telomerase activity was determined in
each sample using 0.5, 0.25 and 0.125mg of protein extract and normalized with the
internal control included in the assay38.
Ultra-bright telomere spots in paraffin-embedded tissue. Ultra-bright telomere
spots were detected by FISH on paraffin-embedded tissue slides. The Histology
FISH Accessory Kit (DAKO) was used following the manufacturer’s instructions.
A telomere-specific PNA-Cy3-labelled probe (DAKO) was used for the detection
of ubs42. Tissue images were captured using a CCD camera with focus motor
(Photometrics SenSys camera) connected to a PC running the Cytovision image
analysis system (Applied Imaging Ltd., UK) and Z-stack software.
G-strand binding and co-immunoprecipitation assays. The TNT-coupled
reticulocyte lysate kit (Promega) was used to in vitro synthesize MYC-POT1,
MYC-POT1R117C, MYC-POT1DOB1, FLAG-TPP1 and FLAG-TPP1OBD
(refs 12,27). For co-immunoprecipitation assays, 3 ml of either MYC-POT1,
MYC-POT1R117C or MYC-POT1DOB1 with either 3 ml of either FLAG-TPP1 or
FLAG-TPP1OBD translation reaction and incubated at 37 C for 20min. About
500 ml of NETN buffer (20mM Tris pH 8.0, 100mM NaCl, 1mM EDTA, 0.5%
NP-40) and 1 mg of anti-MYC (9E10) were added to each protein mix and
incubated at 4 C. The antibody complexes were pulled down with protein A/G
agarose beads, washed four times with NETN and eluted with 40 ml 2 SDS
loading buffer. The eluted proteins (10 ml) were separated by SDS–PAGE, trans-
ferred to nitrocellulose membranes and probed with a monoclonal FLAG antibody.
DNA-binding assays were performed in 20 ml reaction mixtures, 5 ml of each
translation reaction was incubated with 10 nM 50-[32P]-labelled telomeric
oligonucleotide containing seven TTAGGG repeats, 1 mg of the nonspecific
competitor DNA poly (dI-dC) and 2 ml of anti c-MYC (9E10) (C-40, Santa Cruz
Biotechnology) in binding buffer (25mM HEPES-NaOH pH 7.5, 100mM NaCl,
1mM EDTA and 5% glycerol)23. Reactions were incubated for 10min at room
temperature, and protein-DNA complexes were analysed by electrophoresis on a
6% polyacrylamide Tris-borate EDTA gel run at 80V for 3 h.
Statistics. Significance of expression differences among individuals grouped
according to genotype (wt versus mutation carriers) was evaluated with the
non-parametric Kolmogorov–Smirnov test to determine normal distribution of
values within the groups. Student’s t-test was used for comparison of normally
distributed values among genotypes. Differences were considered to be significant
when the exact P value was o0.05.
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Study approval. Written informed consent was received from participants prior to
inclusion in the study.
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